- Home
- CTO vs SLBT Comparison
CTO vs SLBT Comparison
Compare CTO & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTO | SLBT |
|---|---|---|
| Founded | 1902 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 772.2M | 644.9M |
| IPO Year | 1995 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CTO | SLBT |
|---|---|---|
| Price | $19.84 | $1.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $24.00 | N/A |
| AVG Volume (30 Days) | ★ 340.0K | 40.1K |
| Earning Date | 10-27-2026 | 10-26-2026 |
| Dividend Yield | ★ 7.61% | N/A |
| EPS Growth | ★ 122.86 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $149,545,000.00 | N/A |
| Revenue This Year | $20.14 | N/A |
| Revenue Next Year | $10.71 | N/A |
| P/E Ratio | $66.50 | ★ N/A |
| Revenue Growth | ★ 20.10 | N/A |
| 52 Week Low | $16.91 | $1.02 |
| 52 Week High | $22.71 | $6.25 |
Technical Indicators
Market Signals| Indicator | CTO | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 32.87 |
| Support Level | $19.49 | $1.02 |
| Resistance Level | $20.08 | $1.75 |
| Average True Range (ATR) | 0.50 | 0.16 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 62.17 | 27.40 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About SLBT SL Science Holding Limited Ordinary Shares
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.